Red blood cell Much of this potential appears to be contributed by the exposed sialic acid residues in the membrane: their removal results in zeta potential of −6.06 mV. When red blood cells undergo shear stress in constricted vessels, they release ATP, which causes the vessel walls to relax and dilate so as to promote normal blood flow. When their hemoglobin molecules are deoxygenated, red blood cells release S-nitrosothiols, which also act to dilate blood vessels, thus directing more blood to areas of the body depleted of oxygen. Red blood cells can also synthesize nitric oxide enzymatically, using L-arginine as substrate, as do
Genetically engineered blood protein and a substance of choice, such as a small-molecule therapeutic agent or an antibody. The modifications leave the cells and their surfaces otherwise intact. One application is to engineer red blood cells into drug-delivery vehicles. Mature red cells carry no genetic material, potentially presenting fewer safety risks than other gene and cell therapies. Human red blood cells circulate for as long as four months, meaning they could potentially form the basis of long-term therapies. The cells move throughout body via the bloodstream and are unnoticed by the immune system. Genetically engineered blood Genetically engineered blood is blood that has